Daniel Eiger

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Venues

Cancers

ESMO open

Anais brasileiros de dermatologia

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Institut Jules Bordet

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Institut Jules Bordet Sep 01 2018

Belgium

Clinical Research Fellow :: Academic Promoting Team

Publications

Diogo Martins-Branco, Marie Kassapian, Veronique Debien, Rafael Caparica, Daniel Eiger, Urania Dafni, Charitini Andriakopoulou, Sarra El-Abed, Susan L Ellard, Miguel Izquierdo, Malou Vicente, Saranya Chumsri, Martine J Piccart, Alvaro Moreno-Aspitia, Ann Søegaard Knop, Janine Lombard, Evandro de Azambuja
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study. Breast cancer research and treatment (2023)
Chau T Dang, Michael S Ewer, Suzette Delaloge, Jean-Marc Ferrero, Ramon Colomer, Luis de la Cruz-Merino, Theresa L Werner, Katherine Dadswell, Mark Verrill, Daniel Eiger, Sriparna Sarkar, Sanne Lysbet de Haas, Eleonora Restuccia, Sandra M Swain
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers 14 (11) (2022)
Jens Huober, Carlos Henrique Barrios, Naoki Niikura, Michal Jarzab, Yuan-Ching Chang, Shannon L Huggins-Puhalla, José Pedrini, Lyudmila Zhukova, Vilma Graupner, Daniel Eiger, Volkmar Henschel, Nino Gochitashvili, Chiara Lambertini, Eleonora Restuccia, Hong Zhang, null null
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (25) (2022)
Daniel Eiger, Elisa Agostinetto, Rita Saúde-Conde, Evandro de Azambuja
The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers 13 (5) (2021)
Daniel Eiger, Mariana Brandão, Evandro de Azambuja
Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. ESMO open 5 (2) (2021)
Daniel Eiger, Maria Alice Franzoi, Noam Pondé, Mariana Brandão, Claudia de Angelis, Melanie Schmitt Nogueira, Quentin de Hemptinne, Evandro de Azambuja
Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO open 5 (1) (2021)
Daniel Eiger, Marcio Wagner, Noam Falbel Pondé, Melanie Schmitt Nogueira, Laurence Buisseret, Evandro de Azambuja
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta oncologica (Stockholm, Sweden) 59 (6) (2020)
Daniel Eiger, Daniel Arcuschin de Oliveira, Renato Leão de Oliveira, Murilo Costa Sousa, Mireille Darc Cavalcante Brandão, Renato Santos de Oliveira Filho
Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: a critical review. Anais brasileiros de dermatologia 93 (4) (2018)

Daniel Eiger.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Eiger